13 Potential Blockbuster Drugs and Gamechangers to Watch in 2024

Clarivate Plc has released its 2024 Drugs to Watch report, featuring 13 cutting-edge therapeutics expected to revolutionize healthcare in the coming year. The highlighted drugs cover a range of conditions, from sickle cell anemia and multiple myeloma to COPD and age-related macular degeneration. Some notable drugs include Aflibercept for treating AMD, DME, and DR with less frequent injections, and Exagamglogene autotemcel and lovotibeglogene autotemcel, groundbreaking gene-editing therapies for sickle cell disease and beta-thalassemia. The report also emphasizes the impact of technologies like CRISPR-Cas9 gene editing and AI/ML in drug development, accelerating innovation in the pharmaceutical landscape. Mike Ward, Global Head of Thought Leadership at Clarivate, notes the report showcases advancements fueling medical breakthroughs and offering hope to patients with unmet needs.